thought uninspir nomin posit result revenue
ep major updat aducanumab alzheim in-lin top-
bottom-lin guidanc clearli aducanumab like remain major near-
term valu driver suspect much biib under-perform year
reaction bla yet file high enthusiasm
surround ctad meet decemb outsid aducanumab approv see
altern capabl provid acceler top-lin growth especi given
recent pipelin setback gosuranemab psp delay xlrp
cia trial set read-out moder perform across
ms portfolio sign ou spinraza start slow due matur
dose dynam forecast top- bottom-lin cagr
respect well large-cap peer respect fair
number differ scenario still need play given potenti vumer
expand protect fumar franchis ms possibl on-going
tecfidera ipr h-w proceed banner bafiertam litig resolv
favor new market entrant ms bristol ozanimod novarti
ofatumumab sma zolgensma risdiplam like add pressur continu
see littl upsid core franchis reiter u/p po
hope submit aducanumab bla soon reiter engag
regul geographi re-dos studi start shortli although
view trial option patient continu treatment phase
choroideremia set read phase
stroke phase data parkinson like
updat model forecast revenu
prior new non-gaap ep estim respect
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
cia cognit impair associ schizophrenia
return capit employ
return equiti
global biotechnolog compani
develop manufactur market therapi
multipl sclerosi oncolog inflammatori
tysabri tecfidera combin
consider share world-wide
rate under-perform given
concern posit compani
commerci portfolio ms franchis
spinraza face meaning commerci
headwind pipelin focus early-
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
million ex per share item
million ex per share item
net incom non-gaap
price object base sum-of-th part npv analysi forecast sale
key product use wacc vari termin growth rate
asset base characterist patent life
assumpt valu entir ms franchis spinraza
collabor revenu biosimilar pipelin net
cash net po
upsid risk po better expect sale tecfidera less eros
avonex plegridi tysabri anticip vumer meaning captur
market share strong durabl spinraza success number early-stag
pipelin program result acceler approv develop
downsid risk greater expect moder ms sale avonex plegridi
tysabri due increas competit rapid eros spinraza market share
sma limit success pipelin mani product fail advanc
approv narrow indic smaller patient popul
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
